452 related articles for article (PubMed ID: 27553599)
21. HbA1c variability predicts cardiovascular complications in type 2 diabetes regardless of being at glycemic target.
Ceriello A; Lucisano G; Prattichizzo F; La Grotta R; Franzén S; Svensson AM; Eliasson B; Nicolucci A
Cardiovasc Diabetol; 2022 Jan; 21(1):13. PubMed ID: 35073913
[TBL] [Abstract][Full Text] [Related]
22. Glycemic control and extended hemodialysis survival in patients with diabetes mellitus: comparative results of traditional and time-dependent Cox model analyses.
Williams ME; Lacson E; Wang W; Lazarus JM; Hakim R
Clin J Am Soc Nephrol; 2010 Sep; 5(9):1595-601. PubMed ID: 20671217
[TBL] [Abstract][Full Text] [Related]
23. Baseline and 1-year interim follow-up assessment of Japanese patients initiating insulin therapy who were enrolled in the cardiovascular risk evaluation in people with type 2 diabetes on insulin therapy study: an international, multicenter, observational study.
Kawamori R; Node K; Hanafusa T; Atsumi Y; Naito Y; Oka Y
Cardiovasc Diabetol; 2013 Sep; 12():131. PubMed ID: 24011395
[TBL] [Abstract][Full Text] [Related]
24. Guidelines ease up on glycemic control for some patients with type 2 diabetes.
Mitka M
JAMA; 2012 Jun; 307(21):2243-4. PubMed ID: 22706812
[No Abstract] [Full Text] [Related]
25. [Glycemic control and cardiovascular benefit: What do we know today?].
Hanefeld M; Schönauer M; Forst T
Dtsch Med Wochenschr; 2010 Feb; 135(7):301-7. PubMed ID: 20146161
[TBL] [Abstract][Full Text] [Related]
26. Meta-analysis of the effect of herbal supplement on glycemic control in type 2 diabetes.
Suksomboon N; Poolsup N; Boonkaew S; Suthisisang CC
J Ethnopharmacol; 2011 Oct; 137(3):1328-33. PubMed ID: 21843614
[TBL] [Abstract][Full Text] [Related]
27. Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDR® Research to Practice project.
Arnold SV; Inzucchi SE; Tang F; McGuire DK; Mehta SN; Maddox TM; Goyal A; Sperling LS; Einhorn D; Wong ND; Khunti K; Lam CS; Kosiborod M
Eur J Prev Cardiol; 2017 Oct; 24(15):1637-1645. PubMed ID: 28870145
[TBL] [Abstract][Full Text] [Related]
28. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme.
Johansen OE; Neubacher D; von Eynatten M; Patel S; Woerle HJ
Cardiovasc Diabetol; 2012 Jan; 11():3. PubMed ID: 22234149
[TBL] [Abstract][Full Text] [Related]
29. Comprehensive elaboration of glycemic variability in diabetic macrovascular and microvascular complications.
Sun B; Luo Z; Zhou J
Cardiovasc Diabetol; 2021 Jan; 20(1):9. PubMed ID: 33413392
[TBL] [Abstract][Full Text] [Related]
30. Diabetes: glycated hemoglobin is a marker of diabetes and CVD risk.
Wareham NJ; Pfister R
Nat Rev Cardiol; 2010 Jul; 7(7):367-8. PubMed ID: 20577298
[TBL] [Abstract][Full Text] [Related]
31. Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression.
Maiorino MI; Longo M; Scappaticcio L; Bellastella G; Chiodini P; Esposito K; Giugliano D
Cardiovasc Diabetol; 2021 Oct; 20(1):210. PubMed ID: 34663316
[TBL] [Abstract][Full Text] [Related]
32. Insulin initiation and intensification: insights from new studies.
Kumar A; Kalra S
J Assoc Physicians India; 2011 Apr; 59 Suppl():17-22. PubMed ID: 21818994
[TBL] [Abstract][Full Text] [Related]
33. [Typ 2 diabetes: glucose centered therapy is obsolete].
Reincke M; Seissler J
MMW Fortschr Med; 2008 May; 150(18):26-7. PubMed ID: 18533604
[No Abstract] [Full Text] [Related]
34. From glucose lowering agents to disease/diabetes modifying drugs: a "SIMPLE" approach for the treatment of type 2 diabetes.
Mosenzon O; Del Prato S; Schechter M; Leiter LA; Ceriello A; DeFronzo RA; Raz I
Cardiovasc Diabetol; 2021 Apr; 20(1):92. PubMed ID: 33910583
[TBL] [Abstract][Full Text] [Related]
35. Glycemic control in type 2 diabetes: time for an evidence-based about-face?
Montori VM; Fernández-Balsells M
Ann Intern Med; 2009 Jun; 150(11):803-8. PubMed ID: 19380837
[TBL] [Abstract][Full Text] [Related]
36. Effect of patients' risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes mellitus.
Vijan S; Sussman JB; Yudkin JS; Hayward RA
JAMA Intern Med; 2014 Aug; 174(8):1227-34. PubMed ID: 24979148
[TBL] [Abstract][Full Text] [Related]
37. Update on the Canadian Diabetes Association 2008 clinical practice guidelines.
Bhattacharyya OK; Estey EA; Cheng AY;
Can Fam Physician; 2009 Jan; 55(1):39-43. PubMed ID: 19155364
[No Abstract] [Full Text] [Related]
38. Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes.
Tandon N; Ali MK; Narayan KM
Am J Cardiovasc Drugs; 2012 Feb; 12(1):7-22. PubMed ID: 22217193
[TBL] [Abstract][Full Text] [Related]
39. Non-alcoholic fatty liver disease and type 2 diabetes: Importance of glycemic control.
Bloomgarden Z
J Diabetes; 2017 Aug; 9(8):722-723. PubMed ID: 28513098
[No Abstract] [Full Text] [Related]
40. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
Lancet; 1998 Sep; 352(9131):837-53. PubMed ID: 9742976
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
